GI Neuromuscular Pathology Prospective Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02165059|
Recruitment Status : Recruiting
First Posted : June 17, 2014
Last Update Posted : October 13, 2017
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Indiana University GI Neuromuscular Pathology Prospective Registry|
|Study Start Date :||December 2013|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2020|
Patients undergoing surgical full thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of GI neuromuscular disorder.
Patient undergoing esophagectomy, sleeve gastrectomy for obesity, Roux-en-Y gastric bypass, Whipple surgery, transplant surgery.
Patients who are organ donors and undergoing surgery are also part of the control group.
- Clinical data at 4 time periods for study patents will be measured [ Time Frame: 2 years ]
Follow up clinical data will be obtained before, 6 months, 1.5 years, and 2 years after the full thickness biopsy.
Follow up clinical data PAGI-SYM Overall Treatment Effect by Patient Overall Treatment Effect by Physician
- Positive Clinical Outcome to surgical implantation of GES measured by GCSI [ Time Frame: 6 months ]Responders will be defined as >50% improvement of the GCSI total score at 6 month after surgical GES
- Neuromuscular pathology results of the gastric body and proximal jejunum wil be compared between the following groups [ Time Frame: 6 months ]
Patients with gastroparesis from type 1 DM versus patients with idiopathic gastroparesis.
Patients with gastroparesis from type I DM versus gastroparesis from type 2 DM
- Correlation of Pathology Results and Questionnaire [ Time Frame: 6 months ]Neuromuscular pathology results of the gastric body and proximal jejunum will be correlated with the following: Symptom severity (GCSI total score), predominant symptom presentation, severity of delayed gastric emptying.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02165059
|Contact: Anita Gupta, MBBS, MPHfirstname.lastname@example.org|
|Contact: Miranda Williams, BSemail@example.com|
|United States, Indiana|
|Indiana University Hosptial||Recruiting|
|Indianapolis, Indiana, United States, 46202|
|Contact: Anita Gupta, MBBS, MPH 317-948-9227 firstname.lastname@example.org|
|Sub-Investigator: Tom V Nowak, MD|
|Sub-Investigator: Attila Nakeeb, MD|
|Sub-Investigator: Paul Herring, PhD|
|Sub-Investigator: Muhammad T Idress|
|Sub-Investigator: Chandrashekhar A Kubal, MD|
|Sub-Investigator: Jennifer Choi, MD|
|Sub-Investigator: Andrea Shin, MD/Fellow|
|Principal Investigator:||John M Wo, MD||Indiana University|